AUA Guidelines: Genitourinary Syndrome of Menopause

AUA Guidelines: Genitourinary Syndrome of Menopause  Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Tracey S. Wilson, MD & Una J. Lee, MD Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025) Kaufman MR, Ackerman LA, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 0(0). doi:10.1097/JU.0000000000004589. https://www.auajournals.org/doi/10.1097/JU.0000000000004589

LG-IR-NMIBC Treatment Landscape Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Chad R. Ritch, MD, MBA, FACS CME Available: auau.auanet.org/node/44036 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning. 2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC. 3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.

Core Curriculum: Surgical Management of Urolithiasis AUA Urology Core Curriculum: auau.auanet.org/core Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Marcelino E. Rivera, MD and T. Max Shelton, MD Outline: Segment 1: Acute Stone Event and Radiographic Evaluation Segment 2: Shock Wave Lithotripsy Segment 3: Ureteroscopy Segment 4: Percutaneous Nephrolithotomy Segment 5: Intracorporeal Lithotripsy Segment 6: Special Considerations

AUA2025: Key Takeaways: BPH Presenters: Bilal Chughtai, MD & Dean S. Elterman, MD, MSc, FRCSC

AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS

AUA Guidelines: Recurrent Uncomplicated Urinary Tract Infections in Women Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: A. Lenore Ackerman, MD, PhD & Melissa R. Kaufman, MD, PhD Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025) Ackerman AL, Bradley M, D’Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004723

Anorectal Malformation AUA Urology Core Curriculum: auau.auanet.org/core Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Christina Ho, MD and Molly E. Fuchs, MD Outline: Segment 1: Anorectal Malformation Overview/Background Segment 2: Initial Evaluation and Management Segment 3: Cloacal Malformations Segment 4: Long-Term Bladder Management & Concern for CKD Segment 5: Other Considerations

AUA2025: Key Takeaways: Endourology/Stones Highlights Presenters: Davis Viprakasit, MD & Stephen Nakada MD, FACS, FRCS

Update Series (2025) Lesson 30: Beyond Ureteropelvic Junction: Case-Based Tips and Tricks in Robotic Ureteral Stricture Reconstructive Surgery Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

The Latest Breakthroughs in LG-IR-NMIBC (2025) CME Available: auau.auanet.org/node/43689 After participating in this CME activity, participants will be able to: 1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes. 2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns. 3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments. 4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval). 5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies. 6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery. ACKNOWLEDGEMENTS Support provided by an independent educational grant from: UroGen Pharma, Inc.